RIPK1

Across TCGA pan-cancer cohorts, RIPK1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RIPK1 data layer compared with 18 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RIPK1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RIPK1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, GBM, and HNSC are the cancer types where RIPK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.501	0.787	.014	19	view →
GBM	DFS	Quartile	All	0.558	0.849	.003	5	view →
HNSC	OS	Median	IV	0.828	0.634	.029	4	view →
PDAC	OS	Quartile	IV	0.178	0.905	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RIPK1–LUAD (OS)

Open the LUAD breakdown →